ライフサイエンスコーパス: arsenical

1 ethylation reaction that yields dimethylated arsenical.

2 trations and proportions of maternal urinary arsenicals.

3 nce to environmental methylated and aromatic arsenicals.

4 nd in trivalent roxarsone and other aromatic arsenicals.

5 than comparable simple inorganic or organic arsenicals.

6 harmacological uses of inorganic and organic arsenicals.

7 ) bond in MAs(III) and in trivalent aromatic arsenicals.

8 anic arsenate but not methylated pentavalent arsenicals.

9 , dependent on diamidines and melaminophenyl arsenicals.

10 c, contribution to the biological effects of arsenicals.

11 exposed to inorganic or methylated trivalent arsenicals.

12 inding complex in cells exposed to trivalent arsenicals.

13 ty to a number of toxic compounds, including arsenicals.

14 nicals producing methylated and dimethylated arsenicals.

15 in as a model protein, the trivalent organic arsenical 1 was found to demonstrate enhanced specificit

16 Arsenicals active in Hh pathway antagonism include arsen

17 To examine the role of PML in mediating arsenical activity, we also tested these agents using mu

18 jugative R-factor R773 confers resistance to arsenical and antimonial compounds in Escherichia coli,

19 e Escherichia coli plasmid R773 that confers arsenical and antimonial resistance is negatively regula

20 Arsenicals and antimonials are first line drugs for the

21 Leishmania resistant to arsenicals and antimonials extrude arsenite.

22 id-encoded, ATP-dependent extrusion pump for arsenicals and antimonials in Escherichia coli, is allos

23 B pump that is responsible for resistance to arsenicals and antimonials in Escherichia coli.

24 e arsRDABC operon that confers resistance to arsenicals and antimonials in Escherichia coli.

25 ars) operons confer high level resistance to arsenicals and antimonials, while the chromosomally enco

26 n pump that is responsible for resistance to arsenicals and antimonials.

27 trategy for the design of more selective bis-arsenicals and better-optimized protein targets, with a

28 represent the two main classes of drugs, the arsenicals and diamidines, historically used to treat th

29 on protein increases cellular sensitivity to arsenicals and other metalloids and can modulate intrace

30 sformation of inorganic arsenic into organic arsenicals and vice versa.

31 oxicity relative to a small molecule organic arsenical, and an unfunctionalized polymer control.

32 Arsenicals are both environmental carcinogens as well as

33 Arsenicals are painful, inflammatory and blistering caus

34 The effects of arsenicals are usually attributed to their ability to bi

35 Chronic exposure to arsenicals at various life stages and across a range of

36 Arsenicals, at 10 microM, strongly disrupt the oxidative

37 Yet the mechanism by which bis-arsenicals become fluorescent upon binding a Cys4 motif

38 , and pre-steady-state methods, we show that arsenicals bind tightly to low micromolar concentrations

39 ilic inorganic anion, hexafluoroarsenate, an arsenical biocide found recently in wastewater.

40 We found that methylated arsenicals, but not arsenobetaine, are proatherogenic an

41 detoxifies trivalent methylated and aromatic arsenicals by oxidation to pentavalent species.

42 miological studies have shown that inorganic arsenicals cause skin cancers and hyperkeratoses in huma

43 istance to, the diamidine and melaminophenyl arsenical classes of drugs that form the backbone of the

44 gene were also found to be more sensitive to arsenical compounds compared with p-null cell lines.

45 important causal role in the genotoxicity of arsenical compounds in mammalian cells.

46 Dyes and arsenical compounds that displayed selectivity against t

47 inhibition of the innate immune response for arsenical compounds that have been used as therapeutics

48 S. putrefaciens thiolated methylated arsenicals, converting MAs(V) into the more toxic metabo

49 no-glutathione) is a promising novel organic arsenical currently undergoing clinical studies in vario

50 The toxicological effects of arsenicals depend on their oxidation state, chemical com

51 hylated arsenicals (MMAs), and %dimethylated arsenicals (DMAs).

52 Cessation of arsenical drug use could reduce exposure and the burden

53 development of new more potent and selective arsenical drugs against solid tumors.

54 ed sensitive assays that use the fluorescein arsenical dye FlAsH (fluorescein arsenical hairpin binde

55 These bis-arsenical dyes can become fluorescent when bound to a pr

56 lytic subunit of the Ars pump that catalyzes arsenical extrusion in Escherichia coli, thus providing

57 at can be site-specifically labeled with bis-arsenical fluorophore.

58 opy-driven affinity of trivalent (in)organic arsenicals for closely spaced dithiols has been exploite

59 operon catalyze extrusion of antimonials and arsenicals from cells.

60 stance to both diamidines and melaminophenyl arsenicals from the field, including crossresistance to

61 Using a panel of intramolecular fluorescein arsenical hairpin (FlAsH) bioluminescence resonance ener

62 a GST construct that binds fluorescein-based arsenical hairpin binder (FlAsH) results in significantl

63 the CaM was labeled with a fluorescein-based arsenical hairpin binder (FlAsH) that enables our unambi

64 fluorescein arsenical dye FlAsH (fluorescein arsenical hairpin binder) to detect soluble oligomers an

65 sed YFP to a FRET acceptor, ReAsH (resorufin arsenical hairpin binder), targeted to each alpha1S intr

66 ns, to permit detection with the fluorescein arsenical hairpin binding (FlAsH) dye Lumio green.

67 tagged with tetracysteine-FlAsH (fluorescein arsenical hairpin) (acceptor) expressed in HEK293 cells.

68 id (CA) is labeled with a FlAsH (fluorescein arsenical hairpin) reagent.

69 including isothiocyanates, bisbenzylidenes, arsenicals, heavy metals, and vicinal dithiols, showed h

70 all tetracysteine motifs and the fluorescein arsenical helix binder (FlAsH-PALM).

71 The donor fluorophore FlAsH (Fluorescein Arsenical Helix binder) was attached to a CCPGCC motif i

72 geting of this pathway with darinaparsin, an arsenical in clinical trials, reduced fibrosis through r

73 re used to differentiate iAs from less toxic arsenicals in food matrices.

74 The kinetics of production of methylated arsenicals in reaction mixtures containing enzyme, AdoMe

75 We report here that arsenicals, in contrast, antagonize the Hh pathway by ta

76 senical methylarsenate (MAs(V)) and aromatic arsenicals including roxarsone (4-hydroxy-3-nitrobenzene

77 We discovered that arsenicals, including arsenic trioxide and sodium arseni

78 Exposures to trivalent arsenicals induce phosphorylation of extracellular signa

79 ecapitulates the known human pathogenesis of arsenicals-induced cutaneous inflammation and blistering

80 xide (PAO), a strong oxidant and a prototype arsenical is tested for its suitability to defining mole

81 Melarsoprol, a trivalent arsenical, is the only drug that can be used to cure bot

82 sized and characterized the reactivity of an arsenical-maleimide (As-Mal) that can be efficiently con

83 to defining molecular mechanisms underlying arsenicals-mediated tissue injury.

84 have investigated the effects of the organic arsenical, melarsoprol (a drug used for treatment of try

85 nic arsenic trioxide (As2O3) and the organic arsenical, melarsoprol, were recently shown to inhibit g

86 was methylated to the less toxic methylated arsenicals methylarsenate (MAs(V)), dimethylarsenate (DM

87 rsenite (iAsIII) or the methylated trivalent arsenicals methylarsine oxide (MAsIIIO), or iododimethyl

88 tabolites, measured as %iAs, %monomethylated arsenicals (MMAs), and %dimethylated arsenicals (DMAs).

89 position after inorganic arsenic, methylated arsenical, or arsenobetaine exposure in drinking water.

90 mbrane-permeating, vicinal cysteine-bridging arsenical phenylarsine oxide.

91 insecticide approximately 150 years ago: The arsenical poison Paris Green was green in color but defi

92 istent with a scheme in which monomethylated arsenical produced from arsenite is the substrate for a

93 r of a methyl group from AdoMet to trivalent arsenicals producing methylated and dimethylated arsenic

94 Arsenicals provided protection against NLRP1-dependent a

95 , monomethylarsenous acid (MMA), and an aryl arsenical (PSAO)) have been tested with three reduced se

96 ArsA is the catalytic subunit of the arsenical pump, coupling ATP hydrolysis to the efflux of

97 A recent study takes advantage of arsenical reagent-based methodologies to monitor in vivo

98 , is one of the five proteins encoded by the arsenical resistance (ars) operon of plasmid R773 in cel

99 The plasmid-encoded arsenical resistance (ars) operon of plasmid R773 produc

100 The arsenical resistance (ars) operon of the conjugative R-f

101 Plasmid-encoded arsenical resistance (ars) operons confer high level res

102 Arsenical resistance (ars) operons produce resistance to

103 or that regulates expression of the arsRDABC arsenical resistance operon of plasmid R773 in Escherich

104 re this topology, as will ACR2, a eukaryotic arsenical resistance protein.

105 xpression of the ACR2 and ACR3 genes confers arsenical resistance.

106 nic and antimony are related metalloids, and arsenical resistant Leishmania strains are frequently cr

107 Arsenicals (roxarsone and nitarsone) used in poultry pro

108 and increasing dietary diversity may reduce arsenical skin lesion risk in Bangladesh.

109 ng, socioeconomic status, betel nut use, and arsenical skin lesions status.

110 ic toxicity, potentially influencing risk of arsenical skin lesions.

111 rr promoter region was impaired by trivalent arsenicals such as arsenite and phenylarsine oxide.

112 nsively utilized as herbicides, and aromatic arsenicals such as roxarsone (Rox) are used as growth pr

113 It cleaved the C-As bond in aromatic arsenicals such as the trivalent forms of the antimicrob

114 Phenylarsine oxide (PAO), a trivalent arsenical that interacts with vicinal dithiols, is most

115 nzenearsonic acid) is a pentavalent aromatic arsenical that is used as antimicrobial growth promoter

116 mp, coupling ATP hydrolysis to the efflux of arsenicals through the ArsB membrane protein.

117 ing that PAO could be used as a prototype of arsenicals to define the molecular pathogenesis of chemi

118 antly associated with the sum of the urinary arsenicals (U-tAs).

119 ATPase as a consequence of binding trivalent arsenicals under a variety of conditions.

120 in which it is found (e.g., toxic inorganic arsenicals vs nontoxic arsenobetaine), and two analytica

121 In vitro, the organic arsenical was more effective than either arsenite or ant

122 e, known to play a role in detoxification of arsenicals, was diminished by 50% in p-expressing yeast.

123 * Methylated arsenicals were not found in the three plant species exp

124 Volatilized arsenicals were trapped, and the predominant species wer

125 ut did not affect resistance to a lipophilic arsenical, whereas recombinant AQP2 reversed MPXR in cel

126 lective toward trivalent methyl and aromatic arsenicals, with essentially no response to inorganic ar